These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

537 related articles for article (PubMed ID: 28823881)

  • 1. Long-term safety of crisaborole ointment 2% in children and adults with mild to moderate atopic dermatitis.
    Eichenfield LF; Call RS; Forsha DW; Fowler J; Hebert AA; Spellman M; Stein Gold LF; Van Syoc M; Zane LT; Tschen E
    J Am Acad Dermatol; 2017 Oct; 77(4):641-649.e5. PubMed ID: 28823881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults.
    Paller AS; Tom WL; Lebwohl MG; Blumenthal RL; Boguniewicz M; Call RS; Eichenfield LF; Forsha DW; Rees WC; Simpson EL; Spellman MC; Stein Gold LF; Zaenglein AL; Hughes MH; Zane LT; Hebert AA
    J Am Acad Dermatol; 2016 Sep; 75(3):494-503.e6. PubMed ID: 27417017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Crisaborole Topical Ointment, 2% in Adults With Atopic Dermatitis: A Phase 2a, Vehicle-Controlled, Proof-of-Concept Study.
    Murrell DF; Gebauer K; Spelman L; Zane LT
    J Drugs Dermatol; 2015 Oct; 14(10):1108-12. PubMed ID: 26461821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety, Effectiveness, and Pharmacokinetics of Crisaborole in Infants Aged 3 to < 24 Months with Mild-to-Moderate Atopic Dermatitis: A Phase IV Open-Label Study (CrisADe CARE 1).
    Schlessinger J; Shepard JS; Gower R; Su JC; Lynde C; Cha A; Ports WC; Purohit V; Takiya L; Werth JL; Zang C; Vlahos B;
    Am J Clin Dermatol; 2020 Apr; 21(2):275-284. PubMed ID: 32212104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Crisaborole Topical Ointment, 2% in Patients Ages 2 to 17 Years with Atopic Dermatitis: A Phase 1b, Open-Label, Maximal-Use Systemic Exposure Study.
    Zane LT; Kircik L; Call R; Tschen E; Draelos ZD; Chanda S; Van Syoc M; Hebert AA
    Pediatr Dermatol; 2016 Jul; 33(4):380-7. PubMed ID: 27193740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase 2, Randomized, Controlled, Dose-Ranging Study Evaluating Crisaborole Topical Ointment, 0.5% and 2% in Adolescents With Mild to Moderate Atopic Dermatitis.
    Stein Gold LF; Spelman L; Spellman MC; Hughes MH; Zane LT
    J Drugs Dermatol; 2015 Dec; 14(12):1394-9. PubMed ID: 26659931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Crisaborole Ointment, 2%, for the Treatment of Mild-to-Moderate Atopic Dermatitis Across Racial and Ethnic Groups.
    Callender VD; Alexis AF; Stein Gold LF; Lebwohl MG; Paller AS; Desai SR; Tan H; Ports WC; Zielinski MA; Tallman AM
    Am J Clin Dermatol; 2019 Oct; 20(5):711-723. PubMed ID: 31264114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Once-Daily Crisaborole Ointment, 2%, as a Long-Term Maintenance Treatment in Patients Aged ≥ 3 Months with Mild-to-Moderate Atopic Dermatitis: A 52-Week Clinical Study.
    Eichenfield LF; Gower RG; Xu J; Alam MS; Su JC; Myers DE; Sanders P; Vlahos B; Zang C; Lan J; Werth J
    Am J Clin Dermatol; 2023 Jul; 24(4):623-635. PubMed ID: 37184828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic Profile, Safety, and Tolerability of Crisaborole Topical Ointment, 2% in Adolescents with Atopic Dermatitis: An Open-Label Phase 2a Study.
    Tom WL; Van Syoc M; Chanda S; Zane LT
    Pediatr Dermatol; 2016; 33(2):150-9. PubMed ID: 26777394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 1 study of crisaborole in Japanese healthy volunteers and patients with atopic dermatitis.
    Ono R; Yagi M; Shoji A; Fujita K; Yoshida M; Ports WC; Purohit VS
    J Dermatol; 2020 Jan; 47(1):25-32. PubMed ID: 31657024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Crisaborole Ointment 2%: A Review in Mild to Moderate Atopic Dermatitis.
    Hoy SM
    Am J Clin Dermatol; 2017 Dec; 18(6):837-843. PubMed ID: 29076116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subgroup Analysis of Crisaborole for Mild-to-Moderate Atopic Dermatitis in Children Aged 2 to < 18 Years.
    Luger TA; Hebert AA; Zaenglein AL; Silverberg JI; Tan H; Ports WC; Zielinski MA
    Paediatr Drugs; 2022 Mar; 24(2):175-183. PubMed ID: 35292919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Crisaborole Topical Ointment, 2%: A Nonsteroidal, Topical, Anti-Inflammatory Phosphodiesterase 4 Inhibitor in Clinical Development for the Treatment of Atopic Dermatitis.
    Jarnagin K; Chanda S; Coronado D; Ciaravino V; Zane LT; Guttman-Yassky E; Lebwohl MG
    J Drugs Dermatol; 2016 Apr; 15(4):390-6. PubMed ID: 27050693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Crisaborole and its potential role in treating atopic dermatitis: overview of early clinical studies.
    Zane LT; Chanda S; Jarnagin K; Nelson DB; Spelman L; Gold LS
    Immunotherapy; 2016 Jul; 8(8):853-66. PubMed ID: 27283509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of crisaborole in patients with mild-to-moderate atopic dermatitis and other atopic comorbidities.
    Spergel JM; Blaiss MS; Lio P; Kessel A; Cantrell WC; Takiya L; Werth JL; O'Connell MA; Zang C; Cork MJ
    Allergy Asthma Proc; 2021 Sep; 42(5):425-431. PubMed ID: 34474712
    [No Abstract]   [Full Text] [Related]  

  • 16. 2-Year animal carcinogenicity results for crisaborole, a novel phosphodiesterase 4 inhibitor for atopic dermatitis.
    Ciaravino V; Coronado D; Lanphear C; Chanda S
    J Dermatol Sci; 2017 Aug; 87(2):116-122. PubMed ID: 28416366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Topical Agents for the Treatment of Atopic Dermatitis.
    Eichenfield LF; Luger T; Papp K; Silverberg JI; Sierka D; Zang C; Tallman AM; Zielinski MA; Ports WC
    J Drugs Dermatol; 2020 Jan; 19(1):50-64. PubMed ID: 31985912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Topical treatment utilization for patients with atopic dermatitis in the United States, and budget impact analysis of crisaborole ointment, 2.
    Clark R; Bozkaya D; Levenberg M; Faulkner S; Smith TW; Gerber RA
    J Med Econ; 2018 Aug; 21(8):770-777. PubMed ID: 29706103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase 2b, randomized, double-blind, multicenter, vehicle-controlled study to assess the efficacy and safety of two crisaborole regimens in Japanese patients aged 2 years and older with mild-to-moderate atopic dermatitis.
    Fujita K; Yagi M; Moriwaki S; Yoshida M; Graham D
    J Dermatol; 2021 Nov; 48(11):1640-1651. PubMed ID: 34435694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Crisaborole 2% Ointment for Mild-to-Moderate Atopic Dermatitis.
    Riahi A; Lam JM
    Skin Therapy Lett; 2021 Jan; 26(1):1-4. PubMed ID: 33539061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.